key: cord-1003769-3eg6e6kh
authors: Rodrigues, Cristhieni; Freitas-Santos, Rodrigo S; Levi, José Eduardo; Senerchia, Andreza A; Lopes, Ana Tarina A; Santos, Sergio R; Siciliano, Rinaldo F; Pierrotti, Lígia C
title: Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance
date: 2021-08-25
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2021.106428
sha: 4793719c5c165c35d6b8c6a7c69342ee23657328
doc_id: 1003769
cord_uid: 3eg6e6kh

BACKGROUND: : Hydroxychloroquine showed potential to block viral replication of SARS-CoV-2 in in vitro studies. This randomized, double-blinded, placebo controlled clinical trial evaluated the efficacy of hydroxychloroquine plus azithromycin in reducing viral loads in patients with early and mild SARS-CoV-2 infection. METHODS: : A single-center randomized placebo-controlled clinical trial involving outpatients with early and mild SARS-CoV-2 infection was conducted. Inclusion criteria: patients aged between 18 to 65 years with symptoms suggestive of COVID-19 for fewer than five days, no significant comorbidities, and positive naso/oropharyngeal swab screening tests (POCT-PCR). Randomized patients received either hydroxychloroquine for seven days plus azithromycin for five days or placebo. The primary endpoint was viral clearance within a 9-day period. Secondary endpoints included viral load reduction, clinical evolution, hospitalization rates, chest computed tomography evolution and adverse effects. RESULTS: : From 107 potential trial participants, 84 were enrolled following pre-determined criteria. Statistical analyses were performed on an “intention-to-treat” (N=84) and “per-protocol” (PP) basis (N=70). On the PP analysis, the treatment group (N=36) and the placebo group (N=34) displayed similar demographic characteristics. At 95% CI, no statistically significant differences were found between groups in viral clearance rates within a 9-day following enrollment (p-value 0.26). CONCLUSIONS: : Among outpatients with early and mild COVID-19, the use of HCQ/AZT did not impact the time to viral clearance compared to placebo. Secondary outcomes were also not significantly improved with HCQ/AZT treatment compared to placebo. These findings do not support use of HCQ/AZT in this setting.

Globally there have been at the time of writing over 173 million confirmed cases of the novel coronavirus 63 disease , resulting in Severe Acute Respiratory Syndrome caused by SARS-CoV-2 infection, 64 leading to over 3.7 million deaths [1] . Although clinical research for potential therapies and vaccines is 65 underway in several countries, there is currently no effective treatment. Many drugs have been proposed 66 as antiviral agents, including chloroquine, hydroxychloroquine (HCQ), arbidol, remdesivir, and 67 favipiravir, with potential to inhibit SARS-CoV-2 replication in vitro [2, 3] . 68 (Hospital Santa Paula located in São Paulo, Brazil). Participants were enrolled after providing written 93 consent in a hospital emergency room setting. Inclusion criteria: eligible patients were aged between 18 94 and 65 years with mild symptoms suggestive of COVID-19 with an interval from symptoms onset to 95 enrollment of 2 to 5 days and detection of viral RNA in naso/oropharyngeal swabs through a real-time 96 reverse-transcription polymerase chain reaction screening point-of-care test (POCT-PCR). The clinical 97 picture suggestive of COVID-19 was defined as two or more of the following: cough, fever, shortness of 98 breath, nausea/vomiting, diarrhea, body aches, weakness/fatigue, headache, sore throat, runny 99 nose/congestion, sudden gustatory or olfactory loss. Exclusion criteria included: known hypersensitivity 100 to HCQ or azithromycin (AZT), pre-existing pulmonary disease, history of immunosuppression, active 101 cancer diagnosis, pregnancy or lactation, history of cardiac abnormalities or QTc prolongation (QTc > 102 480 ms), known glucose-6-phosphate dehydrogenase (G6PD) deficiency, patients requiring hospital 103 admittance, and patients with inadequate hematological parameters, heart, renal, or liver function. 104

We followed ClinicalTrials.gov definitions of Serious adverse events (SAEs) defined as adverse events 105 that result in death, a life-threatening adverse event, inpatient hospitalization, persistent or significant 106 incapacity or substantial disruption of the ability to conduct normal functions [18] . 107

Complete information on the inclusion and exclusion criteria is provided in the Supplementary Appendix. 108

All study data were collected and managed using the Research Electronic Data Capture (REDCap) system 109 [19] . All data from the participants were adequately anonymized. 110 111

The sample size was calculated using the nSurvival routine from R software [20] . This sample was 113 calculated considering the survival analysis with the Lachin and Foulkes method (1986) [21] based on the 114 follow-up period, the recruitment time and the hazard ratio, comparing control and intervention groups. 115

The following assumptions were considered: study period of 30 days, recruitment period of 30 days, 116 statistical significance level of 5%, 85% power, and 30% of follow-up losses. An aliquot from the emergency department day 0 sample and all samples from the subsequent home visits 134 3, 6 and 9 were processed at the molecular biology lab from Diagnósticos da América S.A. (Dasa, Brazil) . 135

There, an aliquot of 200 µL was extracted by the DSP Virus/Pathogen kit in the automated platform 136

QIAsymphony and eluted in 60 µL. 5 µL of eluate was submitted to real-time reverse-transcription-PCR 137 with primers and probe from the viral E gene in duplex to the cellular control RNAseP, as described [22] 138 employing TaqMan Fast Virus 1-Step Master Mix (ThermoFisher, Brazil). A Ct value of 35 was adopted 139 as the cut-off. This system is referred to as -RT-PCR‖ to distinguish it from the POCT PCR platform used 140 in initial screening. The limit of detection was determined as 408 copies/mL by probit analysis using the 141 ACCUPLEX SARS-COV-2 reference material (0505-0126, Seracare, USA). 142

Eligible patients were randomly assigned (1:1) to receive either HCQ/AZT or placebo. Patients, treating 145 clinicians, and study personnel were all blinded to study group assignment. An independent pharmacist 146 dispensed all trial medications (or placebo) according to a computer-generated randomization list. The 147 therapeutics and placebo were provided in capsule form and identical in appearance. Capsules were pre-148 packed in envelopes and consecutively numbered for each participant according to the randomization 149 schedule. Double-blinding was maintained throughout the trial. 150 151

Following randomization, the participants collected blood sample and were prescribed appropriately. 153

Treatment group participants received two 200 mg HCQ capsules twice a day (BID) for a total course of 154 seven days (i.e. 28 capsules in total) and one 500 mg AZT capsule taken on day 1, followed by one 250 155 mg AZT capsule daily for the next four days (i.e. 6 capsules in total). The placebo capsules were 156 formulated to have similar size, shape, color and taste as hydroxychloroquine and azithromycin capsules, 157 and with an identical dosing regimen. The first dose of medication was given orally to all patients in the 158 emergency department under pharmacist supervision and the remaining doses ingested at home. As 159 standard of care no vitamins or minerals supplement were prescribed. Participants also received 160 instructions regarding social distancing and hygiene to be followed at home and were given 24/7 161 telephonic access to clinical staff in case of questions, symptom evolution or adverse effects. At their 162 homes, participants received telephonic check-up calls on days 3, 6, 9 and between 14-21 days following 163 enrollment, when they responded to symptom and adverse effect questionnaires. On days 3, 6 and 9 164 participants also received visits from diagnostic staff who collected blood samples, performed 165 electrocardiograms, and collected naso/oropharyngeal swabs for RT-PCR testing. In between days 14-21, 166 participants returned to a diagnostic facility where an additional chest computed tomography was 167 performed followed by the telephonic check-up as before. 168

All the nasopharyngeal specimens of the included patients collected to perform the study screening 169 enrollment POCT PCR were also submitted to PCR testing in a central lab in order to obtain the day-0 170 viral load, in order to apply the same molecular method for the primary and secondary virological 171 outcomes. Additionally, enrollment samples were submitted to a molecular assay comprising a panel of The primary outcome was the time (days) to viral clearance within a 9-day evaluation period following 179 enrollment following the onset of symptoms and the study enrollment dates. Viral clearance was defined 180 as a cycle threshold (Ct) greater than 35 by the described RT-PCR assay. Secondary outcomes of interest 181

included: viral load reduction, improvement of symptoms, hospitalization rates, and adverse effects to the 182 trial medications. 183 184

Quantitative variables were described by mean and standard deviation. Categorical variables were 186 described by frequency and proportion. The baseline quantitative variables were described for the total of 187 enrolled patients and the two interventions groups were compared using Student's T-test (for variables 188 observed to have a normal distribution) or using Mann-Whitney test (for variables observed not to have a 189 normal distributed). The categorical variables were compared using Chi-Square test. 190

The primary and secondary outcomes were evaluated both by -intention-to-treat‖ (ITT) analyses and 191 day 0 and were excluded from the PP analysis. In addition, among the remaining trial participants, 2 208 participants from the treatment group failed to continue with trial procedures after day 6 and were also 209 excluded from the PP analysis. The two groups evaluated had similar characteristics at baseline as shown 210

in Table 1 . 211 212

HCQ/AZT and placebo groups viral clearance rates within a 9-day following enrollment were similar in 214 ITT analysis (p-value 0.85). Although there is a numerical difference in the PP analysis, it was not 215

There were no significant differences between the HCQ/AZT and placebo groups in the viral load 219 reduction as measured by the SARS-CoV-2 gene E Ct values at days 3, 6 or 9 (Table 3) . Regarding the 220 clinical response to the treatment, there were no statistically significant differences in the time to 221 improvement of any symptoms evaluated (Table 4) No statistically significant differences were met in clinical outcomes (Table 4) or on viral clearance rates 248 within a 9-day following enrollment between the HCQ/AZT and placebo groups in both ITT (p-value 249 0.85) and PP (p-value 0.26) analysis (Table 2) . 250

The findings are similar to those observed in a published non placebo controlled randomized trial from 251

Spain. In this multicentric study, 157 patients with COVID-19 were enrolled to receive HCQ and 136 252 usual care, within 5 days from symptoms onset. No significant reduction of viral load in nasopharyngeal 253 swabs between arms at day 3 or 7 or clinical improvement was observed [9] . Also, other observational 254 and randomized studies evaluating virological and clinical endpoints have suggested no beneficial effect 255 of HCQ in hospitalized patients with mild to moderate or severe infection by SARS-CoV-2 and a 256 systematic review concluded that the association of AZT to HCQ did not show any benefit, but this is as 257 far as we know the first published study corroborating this results in in outpatients with early and mild 258 No major cardiovascular events related to HCQ/AZT use were observed, however prolongation of QTc 260 interval was more common in treatment group than in the placebo group. It's worth mentioning that the 261 patients included in this study were already expected to have a low risk for cardiovascular events 262 considering their age and lack of comorbidities. Older patients mainly with structural cardiovascular 263 disease might present with higher risk as observed in the Coalition controlled trial study including 667 264 hospitalized patients with mild to moderate COVID-19, in which there was no clinical improvement in 265 patients receiving HCQ alone or associated with AZT. However, prolongation of QTc interval was more 266 common in patients using HCQ with or without AZT [13] . 267

An unexpected loss of 14.3% (n= 12) participants due to discrepancies between POCT-PCR and RT-PCR 268 tests in the same enrollment sample may be attributed to variations in sensitivity, fluctuations in samples 269 with very low viral load, amplicon contamination or other non-identified variables. This POCT-PCR was 270 adopted for the screening of study candidates in order to allow for a faster recruitment, as RT-PCR testing 271 has a much longer turnaround time for results (approximately 72 hours). In the study period, this was the 272 only compact real-time PCR method available in Brazil. Well-known systems like the GenXpert 273 (Cepheid) or ID-Now (Abbott) became available weeks after the end of the study. Since the POCT-PCR 274 is less automated and requires certain manual steps and liquid transfers, it is more susceptible to carry-275 over, what may have contributed to the discrepancies pointed above, resulting in the exclusion in the PP 276 analysis of 12 participants. However, these exclusions haven't changed the overall conclusions since the 277 analysis of ITT and PP groups has shown essentially the same results. 278

This study has some limitations. It was performed in a single center and with loss of 14.3% of the 279 participants. Our patients were from 18 to 65 years old, without comorbidities and in early stage of the 280 disease, which may limit the generalization of our findings and caution should be taken when 281 extrapolating to other populations. 282 HCQ has garnered a large number of supporters during the pandemic, despite several studies not showing 283 its effectiveness [9, 10, 13, 16, 17, 26, 27] . These results could help the scientific community to further 284 judge the benefits and risks for drugs with potential viral activity when used in early stage of Other drugs should be evaluated in combination with other strategies aimed to improve outcomes in these 286

The 

WHO coronavirus disease (COVID-19) dashboard

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Observational study of hydroxychloroquine in hospitalized patients 335 with Covid-19

Association of treatment with hydroxychloroquine or 338 azithromycin with in-hospital mortality in patients with COVID-19 in New York State

in Mild-to-Moderate Covid-19

No evidence of clinical efficacy of hydroxychloroquine 344 in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using 345 routinely collected data to emulate a target trial

Early treatment of COVID-19 patients with 347 hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille

Travel medicine and infectious disease 2020

No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-350 19. Press release from the chief investigators of the Randomised Evaluation of COVid-19

A systematic review and meta-analysis on 356 chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-357 19 treatment

ClinicalTrials.gov -Basic Results‖ Data Element Definitions

The REDCap consortium: Building an international 362 community of software platform partners

R: A language and environment for statistical computing. R Foundation for Statistical 365

Evaluation of sample size and power for analyses of survival with 368 allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

Detection of 2019 novel coronavirus (2019-nCoV) by 371 real-time RT-PCR

Pharmacokinetics and Pharmacological Properties of 373

Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection

In vitro antiviral activity and projection of optimized dosing design 376 of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 377 (SARS-CoV-2)

Towards optimization of hydroxychloroquine 379 dosing in intensive care unit COVID-19 patients

A randomized trial of hydroxychloroquine as 382